Omeros (NASDAQ:OMER) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04), Fidelity Earnings reports. The company had revenue of $4.61 million for the quarter, compared to the consensus estimate of $3.07 million. During the same quarter in the prior year, the firm earned ($0.16) earnings per share.
OMER stock traded down $3.00 during mid-day trading on Friday, hitting $13.02. The company had a trading volume of 5,656,225 shares, compared to its average volume of 613,109. The firm has a market cap of $793.47 million, a price-to-earnings ratio of -16.48 and a beta of 3.79. Omeros has a 12 month low of $8.36 and a 12 month high of $27.00.
In other Omeros news, VP Marcia S. Kelbon sold 7,529 shares of Omeros stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $25.75, for a total value of $193,871.75. Following the sale, the vice president now owns 227,645 shares of the company’s stock, valued at $5,861,858.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 12.10% of the company’s stock.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.